Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biogen

130.65
-1.6600-1.25%
Post-market: 130.650.00000.00%19:59 EDT
Volume:1.21M
Turnover:158.19M
Market Cap:19.14B
PE:12.92
High:132.49
Open:130.87
Low:130.11
Close:132.31
Loading ...

Entrada Therapeutics Appoints Maha Radhakrishnan, M.d., to Its Board of Directors

THOMSON REUTERS
·
03 Jun

Biogen Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
03 Jun

Biogen Inc. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
31 May

Biogen Inc. Stock Climbs 4.1%, Outperforms Competitors

Dow Jones
·
30 May

BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EDT on 2025-05-29

Reuters
·
29 May

Biogen Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
28 May

Biogen’s Strategic Collaboration with City Therapeutics: A Buy Rating for Long-term Growth in RNAi Therapeutics

TIPRANKS
·
28 May

Biogen to Pay $46M in RNAi-Development Collaboration

Dow Jones
·
27 May

BRIEF-Biogen And City Therapeutics Announce Strategic Research Collaboration To Develop Select Novel Rnai-Based Therapies

Reuters
·
27 May

Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel Rnai-Based Therapies

THOMSON REUTERS
·
27 May

Biogen Inc - City Therapeutics to Receive $46 Mln in Payments

THOMSON REUTERS
·
27 May

Biogen Inc. Stock Underperforms Wednesday When Compared To Competitors

Dow Jones
·
22 May

Biogen Inc. Stock Rallies 3.1%, Outperforms Competitors

Dow Jones
·
20 May

U.S. RESEARCH ROUNDUP-Advansix, Cognizant, Inozyme Pharma

Reuters
·
19 May

Biogen Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
16 May

Market Chatter: Eisai, Biogen to Shift Some Lecanemab Ingredient Production to US Amid Tariff Concerns

MT Newswires Live
·
15 May

Biogen Inc. Stock Underperforms Wednesday When Compared To Competitors

Dow Jones
·
15 May

Stoke Therapeutics: Promising Future with Strategic Biogen Partnership and Strong Market Potential for Lead Asset

TIPRANKS
·
14 May

Stoke Therapeutics Initiates Phase 3 Trial for Zorevunersen, Aiming to Launch First Disease-Modifying Treatment for Dravet Syndrome by Mid-2028

Reuters
·
13 May

Stoke Therapeutics Inc. Reports Q1 2025 Results: No Significant Changes in Sales, Revenue, or EPS Noted

Reuters
·
13 May